Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The phrase “Non-target bystander RNA” is not the name of a specific molecule, receptor, gene, or defined RNA family, but a descriptive term used in the genome-editing and RNA‑editing literature to denote RNAs that are unintentionally affected when a programmable nuclease or editor acts on its intended target RNA or DNA.[1][4][5][7][10][18] In CRISPR–Cas13 and similar RNA‑targeting systems, binding of the intended target RNA activates the nuclease, which can then cleave additional, non‑target (“bystander”) RNAs in trans; these molecules are commonly referred to as bystander RNAs or non‑target RNAs and are discussed as off‑target substrates or collateral damage rather than as a discrete biological entity.[1][5][7][18] In base editing and ADAR‑mediated RNA editing, “bystander editing” similarly refers to editing of nearby, non‑intended nucleotides within the editing window, again describing an off‑target effect on generic RNA substrates rather than a specific RNA species.[4][10] Consequently, “Non-target bystander RNA” should not be treated as a canonical therapeutic target but as a generic label for unintended RNA substrates in off‑target or collateral activity studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-target bystander RNA.